ERBB2 and neoplasm: The administration of CAdTrio, in combination with HER2.CAR T cells, facilitated the achievement of dual targeting of two tumor antigens through the engagement of separate receptor classes (CAR and native receptor [TCR]), thereby enhancing therapeutic outcomes (127).